Summit Therapeutics Warns of Cash Crunch That Could Threaten Operations Despite Strong Cancer Drug Progress

Summit Therapeutics says its cash won’t cover operations for a year, raising going-concern concerns. Shares fall as the company seeks funding while advancing ivonescimab development.